Screener
DBV Technologies DBVT VIASKIN® Peanut — Research and development expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by DBV Technologies in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: DBV Technologies’s 10-Q, filed July 16, 2026.
- Filed
- Jul 16, 2026, 4:08 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-048453
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Clinical studies | 9.9 | 16.3 | 21.3 | 23.1 |
| BLA & Regulatory | 5.6 | 2.3 | 11.9 | 3.7 |
| Medical Affairs & Other Medical | 5.1 | 2.0 | 10.0 | 4.0 |
| Research & Innovation | 0.8 | 0.3 | 1.1 | 1.1 |
| Manufacturing & Supply and Quality | 9.9 | 12.8 | 20.4 | 23.4 |
| Sales & Marketing | 5.5 | 0.4 | 10.4 | 0.7 |
| General & Administrative | 14.6 | 8.5 | 25.1 | 14.1 |
| Total expenses | 51.3 | 42.6 | 100.1 | 70.0 |
Item 1C. Condensed Consolidated Statements of Financial Position (Unaudited) as of
FAQ
- What is DBV Technologies's VIASKIN® peanut — research and development expense?
- DBV Technologies (DBVT) reported VIASKIN® peanut — research and development expense of $9.9M in Q2 2026.
- How has DBV Technologies's VIASKIN® peanut — research and development expense changed year-over-year?
- DBV Technologies's VIASKIN® peanut — research and development expense decreased by 39.3% year-over-year, from $16.3M to $9.9M.
- What is the long-term trend for DBV Technologies's VIASKIN® peanut — research and development expense?
- Over 2 years (2023 to 2025), DBV Technologies's VIASKIN® peanut — research and development expense has grown at a 400.9% compound annual growth rate (CAGR), from $2.06M to $51.63M.
- What does VIASKIN® peanut — research and development expense mean?
- Represents the total costs incurred for research and development activities specifically allocated to the Viaskin Peanut product candidate. This includes expenses related to scientific discovery, preclinical testing, and internal research efforts aimed at advancing the therapeutic platform. Monitoring this metric helps investors assess the company's investment intensity in its primary clinical-stage asset.
Ask your AI about DBV Technologies's viaskin® peanut — research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude